Literature DB >> 21268364

[Cross-regulation in development of neuroendocrine and immune systems].

L A Zakharova.   

Abstract

Cross-regulatory effects of immune and neuroendocrine systems on their appearance and functioning occur during a whole life period. At different stages of ontogenesis, the functions of these systems are diverse. In perinatal ontogenesis hormones, neuropeptides and neurotransmitters control the processes of growth and differentiation of various embryo tissues, particularly lymphoid. In the postnatal period, their functions are mostly in homeostasis maintaining of the immune system in response to changes of the environment. Conversely, transmitters of the immune system, such as cytokines, whose synthesis is increased in inflammation, and thymic peptides, program the development of the neuroendocrine system of the embryo. The perinatal period is crucial for final appearance of these systems. Changes in one of the interacting systems, caused by negative environmental factors at this stage, usually provoke changes in other developing systems for a long period. Plasticity of physiological systems in perinatal development allows the organism to adapt to changed conditions. However, these changes can limit physiological functions in interacting systems and induce the appearance of various pathologies in postnatal life.

Entities:  

Mesh:

Year:  2010        PMID: 21268364

Source DB:  PubMed          Journal:  Ontogenez        ISSN: 0475-1450


  2 in total

Review 1.  Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.

Authors:  Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

Review 2.  Altered Neuroendocrine Immune Responses, a Two-Sword Weapon against Traumatic Inflammation.

Authors:  Ce Yang; Jie Gao; Juan Du; Xuetao Yang; Jianxin Jiang
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.